Intelligent Ebitda vs Research Development Analysis

INBS Stock

USD 1.65 0.02 1.20%

Intelligent Bio financial indicator trend analysis is infinitely more than just investigating Intelligent Bio Solutions recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Intelligent Bio Solutions is a good investment. Please check the relationship between Intelligent Bio Ebitda and its Research Development accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intelligent Bio Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Ebitda vs Research Development

Ebitda vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Intelligent Bio Solutions Ebitda account and Research Development. At this time, the significance of the direction appears to have very week relationship.

The correlation between Intelligent Bio's Ebitda and Research Development is 0.28. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Research Development in the same time period over historical financial statements of Intelligent Bio Solutions, assuming nothing else is changed. The correlation between historical values of Intelligent Bio's Ebitda and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Intelligent Bio Solutions are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebitda i.e., Intelligent Bio's Ebitda and Research Development go up and down completely randomly.

Correlation Coefficient

0.28

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Ebitda

Research Development

Most indicators from Intelligent Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Intelligent Bio Solutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intelligent Bio Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

At this time, Intelligent Bio's Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.30 in 2024, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2024.

	2021	2023	2024 (projected)
Interest Expense	7.5K	167.1K	158.8K
Depreciation And Amortization	966.7K	1.2M	1.4M

Interest Expense Depreciation And Amortization

Intelligent Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Receivables	Common Stock Shares Outstanding	Inventory	Net Tangible Assets	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Net Invested Capital	Short Long Term Debt
Total Assets		-0.79	-0.34	-0.85	0.97	-0.95	-0.78	0.8	0.95	0.95	-0.64	0.54	0.84	-0.26	0.96	-0.86	-0.13	0.93	0.38	-0.92	0.95	0.63	-0.82	0.77	0.95	-0.92
Short Long Term Debt Total	-0.79		0.08	0.74	-0.86	0.85	0.77	-0.57	-0.72	-0.72	0.95	-0.44	-0.93	0.45	-0.69	0.98	0.52	-0.73	-0.42	0.66	-0.73	-0.73	0.64	-0.48	-0.91	0.92
Other Current Liab	-0.34	0.08		0.4	-0.38	0.21	0.56	-0.34	-0.23	-0.23	0.16	0.42	-0.38	0.59	-0.33	0.07	-0.29	-0.23	-0.34	0.13	-0.28	-0.22	0.32	-0.21	-0.34	0.39
Total Current Liabilities	-0.85	0.74	0.4		-0.89	0.9	0.61	-0.63	-0.87	-0.87	0.59	-0.54	-0.75	0.57	-0.88	0.79	0.39	-0.88	-0.43	0.85	-0.75	-0.5	0.53	-0.44	-0.88	0.81
Total Stockholder Equity	0.97	-0.86	-0.38	-0.89		-0.96	-0.85	0.77	0.92	0.92	-0.74	0.5	0.92	-0.41	0.93	-0.89	-0.18	0.9	0.41	-0.88	0.92	0.64	-0.83	0.74	0.99	-0.96
Net Debt	-0.95	0.85	0.21	0.9	-0.96		0.7	-0.69	-0.97	-0.97	0.69	-0.59	-0.83	0.34	-0.96	0.9	0.26	-0.97	-0.51	0.93	-0.91	-0.49	0.75	-0.68	-0.95	0.9
Retained Earnings	-0.78	0.77	0.56	0.61	-0.85	0.7		-0.65	-0.61	-0.61	0.81	-0.05	-0.95	0.48	-0.66	0.74	-0.01	-0.59	-0.37	0.53	-0.76	-0.69	0.84	-0.68	-0.86	0.91
Accounts Payable	0.8	-0.57	-0.34	-0.63	0.77	-0.69	-0.65		0.68	0.68	-0.4	0.5	0.65	0.01	0.73	-0.67	0.13	0.74	0.17	-0.78	0.78	0.63	-0.68	0.66	0.76	-0.76
Cash	0.95	-0.72	-0.23	-0.87	0.92	-0.97	-0.61	0.68		1.0	-0.52	0.62	0.72	-0.24	0.99	-0.8	-0.15	0.97	0.47	-0.95	0.91	0.39	-0.72	0.71	0.88	-0.82
Cash And Short Term Investments	0.95	-0.72	-0.23	-0.87	0.92	-0.97	-0.61	0.68	1.0		-0.52	0.62	0.72	-0.24	0.99	-0.8	-0.15	0.97	0.47	-0.95	0.91	0.39	-0.72	0.71	0.88	-0.82
Non Current Liabilities Total	-0.64	0.95	0.16	0.59	-0.74	0.69	0.81	-0.4	-0.52	-0.52		-0.17	-0.92	0.56	-0.51	0.88	0.51	-0.53	-0.45	0.42	-0.59	-0.71	0.59	-0.38	-0.81	0.86
Other Current Assets	0.54	-0.44	0.42	-0.54	0.5	-0.59	-0.05	0.5	0.62	0.62	-0.17		0.27	0.19	0.57	-0.54	-0.35	0.6	-0.21	-0.77	0.47	0.35	-0.24	0.33	0.48	-0.35
Other Stockholder Equity	0.84	-0.93	-0.38	-0.75	0.92	-0.83	-0.95	0.65	0.72	0.72	-0.92	0.27		-0.53	0.73	-0.9	-0.27	0.71	0.4	-0.65	0.79	0.75	-0.79	0.62	0.95	-0.97
Total Liab	-0.26	0.45	0.59	0.57	-0.41	0.34	0.48	0.01	-0.24	-0.24	0.56	0.19	-0.53		-0.25	0.35	0.47	-0.21	-0.37	0.09	-0.1	-0.31	0.06	0.15	-0.43	0.42
Total Current Assets	0.96	-0.69	-0.33	-0.88	0.93	-0.96	-0.66	0.73	0.99	0.99	-0.51	0.57	0.73	-0.25		-0.77	-0.08	0.97	0.46	-0.95	0.93	0.42	-0.76	0.75	0.89	-0.83
Short Term Debt	-0.86	0.98	0.07	0.79	-0.89	0.9	0.74	-0.67	-0.8	-0.8	0.88	-0.54	-0.9	0.35	-0.77		0.49	-0.82	-0.44	0.77	-0.81	-0.72	0.67	-0.55	-0.94	0.93
Common Stock	-0.13	0.52	-0.29	0.39	-0.18	0.26	-0.01	0.13	-0.15	-0.15	0.51	-0.35	-0.27	0.47	-0.08	0.49		-0.17	-0.08	0.13	0.04	-0.41	-0.25	0.37	-0.27	0.23
Net Receivables	0.93	-0.73	-0.23	-0.88	0.9	-0.97	-0.59	0.74	0.97	0.97	-0.53	0.6	0.71	-0.21	0.97	-0.82	-0.17		0.56	-0.95	0.92	0.39	-0.71	0.69	0.88	-0.83
Common Stock Shares Outstanding	0.38	-0.42	-0.34	-0.43	0.41	-0.51	-0.37	0.17	0.47	0.47	-0.45	-0.21	0.4	-0.37	0.46	-0.44	-0.08	0.56		-0.29	0.48	-0.1	-0.37	0.26	0.43	-0.5
Inventory	-0.92	0.66	0.13	0.85	-0.88	0.93	0.53	-0.78	-0.95	-0.95	0.42	-0.77	-0.65	0.09	-0.95	0.77	0.13	-0.95	-0.29		-0.89	-0.43	0.69	-0.72	-0.84	0.76
Net Tangible Assets	0.95	-0.73	-0.28	-0.75	0.92	-0.91	-0.76	0.78	0.91	0.91	-0.59	0.47	0.79	-0.1	0.93	-0.81	0.04	0.92	0.48	-0.89		0.46	-0.92	0.9	0.9	-0.89
Non Current Assets Total	0.63	-0.73	-0.22	-0.5	0.64	-0.49	-0.69	0.63	0.39	0.39	-0.71	0.35	0.75	-0.31	0.42	-0.72	-0.41	0.39	-0.1	-0.43	0.46		-0.44	0.3	0.71	-0.72
Non Currrent Assets Other	-0.82	0.64	0.32	0.53	-0.83	0.75	0.84	-0.68	-0.72	-0.72	0.59	-0.24	-0.79	0.06	-0.76	0.67	-0.25	-0.71	-0.37	0.69	-0.92	-0.44		-0.96	-0.79	0.83
Other Assets	0.77	-0.48	-0.21	-0.44	0.74	-0.68	-0.68	0.66	0.71	0.71	-0.38	0.33	0.62	0.15	0.75	-0.55	0.37	0.69	0.26	-0.72	0.9	0.3	-0.96		0.68	-0.69
Net Invested Capital	0.95	-0.91	-0.34	-0.88	0.99	-0.95	-0.86	0.76	0.88	0.88	-0.81	0.48	0.95	-0.43	0.89	-0.94	-0.27	0.88	0.43	-0.84	0.9	0.71	-0.79	0.68		-0.98
Short Long Term Debt	-0.92	0.92	0.39	0.81	-0.96	0.9	0.91	-0.76	-0.82	-0.82	0.86	-0.35	-0.97	0.42	-0.83	0.93	0.23	-0.83	-0.5	0.76	-0.89	-0.72	0.83	-0.69	-0.98

Click cells to compare fundamentals

Intelligent Bio Account Relationship Matchups

Intelligent Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.5M	20.4M	12.4M	10.4M	13.8M	8.9M
Short Long Term Debt Total	4.8M	5.1M	5.1M	1.3M	871.4K	827.9K
Other Current Liab	2.1M	2.3M	1.1M	1.5M	1.2M	1.2M
Total Current Liabilities	7.7M	3.7M	4.7M	5.9M	5.5M	4.6M
Total Stockholder Equity	(5.2M)	13.6M	6.6M	3.8M	8.3M	8.7M
Net Debt	4.7M	(12.6M)	(8.2M)	(201.6K)	(5.4M)	(5.2M)
Retained Earnings	(15.8M)	(24.3M)	(31.2M)	(41.8M)	(52.0M)	(49.4M)
Accounts Payable	483.6K	1.4M	715.9K	1.2M	602.3K	792.1K
Cash	427.3K	12.6M	8.2M	1.5M	6.3M	4.1M
Cash And Short Term Investments	427.3K	12.6M	8.2M	1.5M	6.3M	4.1M
Liabilities And Stockholders Equity	2.5M	20.4M	12.4M	10.4M	13.8M	8.9M
Non Current Liabilities Total	5.6M	3.2M	1.1M	783.9K	144.9K	137.7K
Other Current Assets	12.1K	2.4M	163.1K	512.2K	474.3K	586.1K
Other Stockholder Equity	(9.2M)	38.4M	38.4M	46.2M	61.0M	64.0M
Total Liab	7.7M	6.9M	5.8M	6.7M	5.6M	5.1M
Total Current Assets	2.3M	16.4M	10.9M	3.9M	8.5M	6.5M
Accumulated Other Comprehensive Income	(364.0K)	(661.3K)	(788.1K)	(575.5K)	(712.6K)	(677.0K)
Short Term Debt	5.1M	5.1M	137.8K	800.1K	1.1M	1.0M
Common Stock	2.9M	142.3K	148.9K	23.3K	34.6K	32.8K
Net Receivables	19.6K	3.2M	2.5M	833.2K	978.3K	1.2M
Inventory	1.9M	(3.2M)	0.0	979.9K	777.5K	507.4K
Net Tangible Assets	(5.2M)	15.0M	6.6M	(1.5M)	(1.7M)	(1.8M)
Non Current Assets Total	135.7K	4.0M	1.5M	6.5M	5.2M	3.5M
Net Invested Capital	(17.4M)	15.0M	6.6M	4.6M	8.8M	9.3M
Capital Stock	20.2M	148.8K	148.9K	23.3K	34.6K	32.8K
Net Working Capital	(5.4M)	14.5M	6.2M	(2.0M)	3.1M	2.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Intelligent Stock Analysis

When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC